UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051924
Receipt number R000059242
Scientific Title Postoperative anterograde amnesia by remimazolam and antagonism with flumazenil
Date of disclosure of the study information 2023/08/18
Last modified on 2023/12/14 13:51:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Postoperative anterograde amnesia by remimazolam and antagonism with flumazenil

Acronym

Postoperative anterograde amnesia by remimazolam and antagonism with flumazenil

Scientific Title

Postoperative anterograde amnesia by remimazolam and antagonism with flumazenil

Scientific Title:Acronym

Postoperative anterograde amnesia by remimazolam and antagonism with flumazenil

Region

Japan


Condition

Condition

Patients who will undergo general anesthesia for elective surgery of lower limbs

Classification by specialty

Anesthesiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the antagonism effect of flumazenil to anterograde amnesia of remimazolam

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of memory test by flumazenil

Key secondary outcomes

Time course of the score in memory test, Incidence of retrograde amnesia/ postoperative delirium/ postoperative sleep disorder


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

administration of flumazenil

Interventions/Control_2

administration of normal saline (placebo)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Adult patient who will undergo elective surgery
(2) Age 20-75
(3) No gender restriction
(4) Patients who manifest consent for this study

Key exclusion criteria

(1) Patients contraindicate or with allergy to remimazolam or flumazenil
(2) Patients contraindicate to neuraxial block
(3) Patients with cognitive impairment
(4) Patients with intracranial disease or cerebrovascular disease
(5) Patients who take psychiatric medication
(6) Patients who usually take benzodiazepine
(7) ASAPS 3 or 4
(8) Patients decided not to be eligible for this study
(9) Patients administrated flumazenil for clinical reason (not for research protocol)

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Kotoe
Middle name
Last name Kamata

Organization

Tohoku University Hospital

Division name

Department of Anesthesiology

Zip code

980-8575

Address

2-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8575, Japan

TEL

022-717-7321

Email

mattytohoku@gmail.com


Public contact

Name of contact person

1st name Kotoe
Middle name
Last name Kamata

Organization

Tohoku University Hospital

Division name

Department of Anesthisiology

Zip code

980-8575

Address

2-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8575, Japan

TEL

022-717-7321

Homepage URL


Email

mattytohoku@gmail.com


Sponsor or person

Institute

Tohoku University

Institute

Department

Personal name



Funding Source

Organization

No funding sourse

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee Tohoku University Graduate School of Medicine

Address

1-1, Seiryomachi, Aobaku, Sendai, Miyagi, 980-8575, Japan

Tel

022-717-8007

Email

med-kenkyo@grp.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 08 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 08 Month 18 Day

Date of IRB


Anticipated trial start date

2024 Year 12 Month 21 Day

Last follow-up date

2025 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 08 Month 16 Day

Last modified on

2023 Year 12 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059242


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name